10nonemixedZAJA, Francesco; VIANELLI, N; BATTISTA, M; SPEROTTO, A; PATRIARCA, Francesca; TOMADINI, V; FILÌ, C; TANI, M; BACCARANI, M; FANIN, RenatoZaja, Francesco; Vianelli, N; Battista, M; Sperotto, A; Patriarca, Francesca; Tomadini, V; Filì, C; Tani, M; Baccarani, M; Fanin, Renat
Objective: This paper prospectively evaluates the long-term follow-up [mean +/- standard deviation (...
11This prospective study investigated the efficacy, safety, and response duration of low-dose rituxi...
none13noneZaja F; Vianelli N; Volpetti S; Battista ML; Defina M; Palmieri S; Bocchia M; Medeot M; De...
none10noneZaja F; Vianelli N; Battista M; Sperotto A; Patriarca F; Tomadini V; Fili C; Tani M; Bacca...
14OBJECTIVES: To evaluate the efficacy of a salvage treatment with rituximab (RTX) in adults with pr...
7We report the long-term outcome results of 57 consecutive adult patients with immune thrombocytopen...
19Rituximab 375 mg/m2 weekly for four weeks has significant activity in patients with immune thrombo...
10OBJECTIVE: To evaluate the long-term activity and toxicity profile of rituximab in adult patients ...
RITP was a double‐blind randomized, 78‐week follow‐up trial in which 109 adults with immune thromboc...
PubMed ID: 27102929Objective: This paper prospectively evaluates the long-term follow-up [mean ± sta...
3The use of rituximab for the treatment of immune thrombocytopenia was greeted enthusiastically: it ...
International audienceRituximab is a second-line option in adults with immune thrombocytopenia (ITP)...
13Backgrounds: Rituximab 375 mg/m2 weekly for 4 wks has significant activity in adults with primary ...
Objective: This paper prospectively evaluates the long-term follow-up [mean +/- standard deviation (...
11This prospective study investigated the efficacy, safety, and response duration of low-dose rituxi...
none13noneZaja F; Vianelli N; Volpetti S; Battista ML; Defina M; Palmieri S; Bocchia M; Medeot M; De...
none10noneZaja F; Vianelli N; Battista M; Sperotto A; Patriarca F; Tomadini V; Fili C; Tani M; Bacca...
14OBJECTIVES: To evaluate the efficacy of a salvage treatment with rituximab (RTX) in adults with pr...
7We report the long-term outcome results of 57 consecutive adult patients with immune thrombocytopen...
19Rituximab 375 mg/m2 weekly for four weeks has significant activity in patients with immune thrombo...
10OBJECTIVE: To evaluate the long-term activity and toxicity profile of rituximab in adult patients ...
RITP was a double‐blind randomized, 78‐week follow‐up trial in which 109 adults with immune thromboc...
PubMed ID: 27102929Objective: This paper prospectively evaluates the long-term follow-up [mean ± sta...
3The use of rituximab for the treatment of immune thrombocytopenia was greeted enthusiastically: it ...
International audienceRituximab is a second-line option in adults with immune thrombocytopenia (ITP)...
13Backgrounds: Rituximab 375 mg/m2 weekly for 4 wks has significant activity in adults with primary ...
Objective: This paper prospectively evaluates the long-term follow-up [mean +/- standard deviation (...
11This prospective study investigated the efficacy, safety, and response duration of low-dose rituxi...
none13noneZaja F; Vianelli N; Volpetti S; Battista ML; Defina M; Palmieri S; Bocchia M; Medeot M; De...
DOI
Add to ORKG